Neutral impactCorporate Action

Claroid Pharma Files IPO Draft Papers To Offer 1.26 Crore Shares: Here Are The Key Risk Factors

NDTV Profit 2 hrs ago·23 Sept 2026, 12:25 pm

The company plans to utilise the net proceeds from the fresh issue towards funding capital expenditure for setting up a new pharmaceutical manufacturing facility on its existing land.

Key takeaways

  • Category: Corporate Action.

Why it matters

A routine update. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NDTV Profit.

More Stocks news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.